Evidence map›Paper›PMID 31294896›Full record

ArticleHuman mutation2019

Assessment of blind predictions of the clinical significance of BRCA1 and BRCA2 variants.

Melissa S Cline, Giulia Babbi, Sandra Bonache, Yue Cao, Rita Casadio, Xavier de la Cruz, Orland Díez, Sara Gutiérrez-Enríquez, Panagiotis Katsonis, Carmen Lai and 22 more

Abstract read
In one paragraph

Article in Human mutation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Melissa S ClineGenomics Institute, UC Santa Cruz, Santa Cruz, California.ORCID 0000-0002-0148-1956
Giulia BabbiFaBiT Department, Biocomputing Group, University of Bologna, Bologna, Italy.
Sandra BonacheOncogenetics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.ORCID 0000-0002-7395-8143
Yue CaoDepartment of Electrical and Computer Engineering, Texas A&M University, College Station, Texas.
Rita CasadioFaBiT Department, Biocomputing Group, University of Bologna, Bologna, Italy.ORCID 0000-0002-7462-7039
Xavier de la CruzClinical and Translational Bioinformatics Research Unit, Vall d'Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.ORCID 0000-0002-9738-8472
Orland DíezOncogenetics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Sara Gutiérrez-EnríquezOncogenetics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.ORCID 0000-0002-1711-6101
Panagiotis KatsonisDepartment of Medical and Human Genetics, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-7172-1644
Carmen LaiColor Genomics, Burlingame, California.
Olivier LichtargeDepartment of Medical and Human Genetics, Baylor College of Medicine, Houston, Texas.ORCID 0000-0003-4057-7122
Pier L MartelliFaBiT Department, Biocomputing Group, University of Bologna, Bologna, Italy.ORCID 0000-0002-0274-5669
Gilad MishneColor Genomics, Burlingame, California.
Alejandro Moles-FernándezClinical and Translational Bioinformatics Research Unit, Vall d'Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.ORCID 0000-0003-0252-6084
Gemma MontalbanClinical and Translational Bioinformatics Research Unit, Vall d'Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.ORCID 0000-0002-6958-4759
Sean D MooneyBiomedical Informatics and Medical Education, University of Washington, Seattle, Washington.ORCID 0000-0003-2654-0833
Robert O'ConnerSage Bionetworks, Seattle, Washington.
Lars OotesClinical and Translational Bioinformatics Research Unit, Vall d'Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Selen ÖzkanClinical and Translational Bioinformatics Research Unit, Vall d'Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Natalia PadillaClinical and Translational Bioinformatics Research Unit, Vall d'Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Kymberleigh A PagelComputer Science and Informatics, Indiana University, Bloomington, Indiana.ORCID 0000-0001-8544-9250
Vikas PejaverBiomedical Informatics and Medical Education, University of Washington, Seattle, Washington.ORCID 0000-0002-1943-0284
Predrag RadivojacComputer Science and Informatics, Indiana University, Bloomington, Indiana.ORCID 0000-0002-6769-0793
Casandra RieraClinical and Translational Bioinformatics Research Unit, Vall d'Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Castrense SavojardoFaBiT Department, Biocomputing Group, University of Bologna, Bologna, Italy.ORCID 0000-0002-7359-0633
Yang ShenDepartment of Electrical and Computer Engineering, Texas A&M University, College Station, Texas.ORCID 0000-0002-1703-7796
Yuanfei SunDepartment of Electrical and Computer Engineering, Texas A&M University, College Station, Texas.
Scott TopperColor Genomics, Burlingame, California.ORCID 0000-0003-1612-7201
Michael T ParsonsMolecular Cancer Epidemiology, QIMR Berghofer Medical Research Institute, Brisbane, Australia.ORCID 0000-0003-3242-8477
Amanda B SpurdleMolecular Cancer Epidemiology, QIMR Berghofer Medical Research Institute, Brisbane, Australia.ORCID 0000-0003-1337-7897
David E GoldgarHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0003-0697-9347
ENIGMA Consortium

Funding

UCSC Center for Genomic Science, and Minority Outreach ProgramP41HG002371 · NHGRI · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI HAUSSLER, DAVID H · 2001 to 2011
$34.8M
Training SubprojectU54HG007990 · NHGRI · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI HAUSSLER, DAVID H, PATTERSON, DAVID · 2014 to 2018
$14.8M
Functional Determinnats in G Protein-coupled ReceptorsR01GM066099 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI LICHTARGE, OLIVIER · 2003 to 2022
$7.5M
A Knowledge Map to Find Alzheimer's Disease DrugsR01AG061105 · NIA · BAYLOR COLLEGE OF MEDICINE · PI LICHTARGE, OLIVIER · 2018 to 2022
$4.6M
Comparative genomics of protein structure and functionR01GM079656 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI LICHTARGE, OLIVIER · 2007 to 2019
$4.3M
Unraveling molecular and system-level mechanisms of human disease-associated protein mutationsR35GM124952 · NIGMS · TEXAS ENGINEERING EXPERIMENT STATION · PI Yang Shen · 2017 to 2026
$2.9M
Component 2 - Resource ProjectU41HG007346 · NHGRI · UNIVERSITY OF CALIFORNIA BERKELEY · PI BRENNER, STEVEN E · 2015 to 2017
$1.7M
Critical Assessment of Genome Interpretation ConferenceR13HG006650 · NHGRI · UNIVERSITY OF CALIFORNIA BERKELEY · PI BRENNER, STEVEN E · 2011 to 2018
$165k
Newcastle University; NMHRC Senior Research Fellowship ID 1061778NHGRI NIH HHS P41 HG002371NHGRI NIH HHS R13 HG006650NHGRI NIH HHS U41 HG007346NHGRI NIH HHS U54 HG007990NHGRI NIH HHS U54HG007990NIA NIH HHS R01 AG061105NIGMS NIH HHS NIH-GM066099NIGMS NIH HHS NIH-GM079656NIGMS NIH HHS R01 GM066099NIGMS NIH HHS R01 GM079656NIGMS NIH HHS R35 GM124952NIH HHS NIH R13 HG006650NIH HHS NIH R35GM124952NIH HHS NIH U41 HG007346NIH National Institute on Aging R01-AG061105
6 · The paper itself

Abstract

Testing for variation in BRCA1 and BRCA2 (commonly referred to as BRCA1/2), has emerged as a standard clinical practice and is helping countless women better understand and manage their heritable risk of breast and ovarian cancer. Yet the increased rate of BRCA1/2 testing has led to an increasing number of Variants of Uncertain Significance (VUS), and the rate of VUS discovery currently outpaces the rate of clinical variant interpretation. Computational prediction is a key component of the variant interpretation pipeline. In the CAGI5 ENIGMA Challenge, six prediction teams submitted predictions on 326 newly-interpreted variants from the ENIGMA Consortium. By evaluating these predictions against the new interpretations, we have gained a number of insights on the state of the art of variant prediction and specific steps to further advance this state of the art.

Indexed as

BRCA1 ProteinBRCA2 ProteinBreast NeoplasmsComputational BiologyEarly Detection of CancerFemaleGenetic Predisposition to DiseaseGenetic TestingGenetic VariationHumansModels, GeneticOvarian NeoplasmsBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanBRCABRCA1BRCA2CAGICAGI5variant interpretation

Identifiers

PMID31294896
PMCPMC6744348

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.